[1]
Mahajan R, Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian journal of pharmacology. 2009 Aug;
[PubMed PMID: 20523873]
[2]
Defronzo RA, Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes care. 2011 Apr;
[PubMed PMID: 21447659]
[3]
Singh P,Singh M,Cugati G,Singh AK, Hyperprolactinemia: An often missed cause of male infertility. Journal of human reproductive sciences. 2011 May;
[PubMed PMID: 22065670]
[6]
Thorner MO,Chait A,Aitken M,Benker G,Bloom SR,Mortimer CH,Sanders P,Mason AS,Besser GM, Bromocriptine treatment of acromegaly. British medical journal. 1975 Feb 8;
[PubMed PMID: 1111790]
[7]
Cassar J,Mashiter K,Joplin GF, Bromocriptine treatment of acromegaly. Metabolism: clinical and experimental. 1977 May;
[PubMed PMID: 576725]
[8]
Jankovic J, Parkinson's disease: clinical features and diagnosis. Journal of neurology, neurosurgery, and psychiatry. 2008 Apr;
[PubMed PMID: 18344392]
[10]
Stowe RL,Ives NJ,Clarke C,van Hilten J,Ferreira J,Hawker RJ,Shah L,Wheatley K,Gray R, Dopamine agonist therapy in early Parkinson's disease. The Cochrane database of systematic reviews. 2008 Apr 16;
[PubMed PMID: 18425954]
Level 1 (high-level) evidence
[11]
Brooks DJ, Dopamine agonists: their role in the treatment of Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry. 2000 Jun;
[PubMed PMID: 10811688]
[13]
Hisahara S,Shimohama S, Dopamine receptors and Parkinson's disease. International journal of medicinal chemistry. 2011;
[PubMed PMID: 25954517]
[14]
Fitzgerald P,Dinan TG, Prolactin and dopamine: what is the connection? A review article. Journal of psychopharmacology (Oxford, England). 2008 Mar;
[PubMed PMID: 18477617]
[15]
Via MA,Chandra H,Araki T,Potenza MV,Skamagas M, Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy. 2010 Mar 26;
[PubMed PMID: 21437075]
[16]
Holt RI,Barnett AH,Bailey CJ, Bromocriptine: old drug, new formulation and new indication. Diabetes, obesity
[PubMed PMID: 20977575]
[18]
Colao A,Di Sarno A,Guerra E,De Leo M,Mentone A,Lombardi G, Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nature clinical practice. Endocrinology
[PubMed PMID: 16932285]
[19]
Weil C, The safety of bromocriptine in long-term use: a review of the literature. Current medical research and opinion. 1986;
[PubMed PMID: 3516579]
Level 3 (low-level) evidence
[20]
Zanettini R,Antonini A,Gatto G,Gentile R,Tesei S,Pezzoli G, Valvular heart disease and the use of dopamine agonists for Parkinson's disease. The New England journal of medicine. 2007 Jan 4;
[PubMed PMID: 17202454]
[21]
Shivaprasad C,Kalra S, Bromocriptine in type 2 diabetes mellitus. Indian journal of endocrinology and metabolism. 2011 Jul;
[PubMed PMID: 21847449]
[23]
Vermund SH,Goldstein RG,Romano AA,Atwood SJ, Accidental bromocriptine ingestion in childhood. The Journal of pediatrics. 1984 Nov;
[PubMed PMID: 6502320]
[24]
Lemieux-Charles L,McGuire WL, What do we know about health care team effectiveness? A review of the literature. Medical care research and review : MCRR. 2006 Jun;
[PubMed PMID: 16651394]
[25]
Green BN, Johnson CD. Interprofessional collaboration in research, education, and clinical practice: working together for a better future. The Journal of chiropractic education. 2015 Mar:29(1):1-10. doi: 10.7899/JCE-14-36. Epub 2015 Jan 16
[PubMed PMID: 25594446]
[26]
Bridges DR,Davidson RA,Odegard PS,Maki IV,Tomkowiak J, Interprofessional collaboration: three best practice models of interprofessional education. Medical education online. 2011 Apr 8;
[PubMed PMID: 21519399]